

GlaxoSmithKline Consumer Healthcare Ltd.

Patiala Road, Nabha (Punjab) 147201

T (01765) 306400

F (01765) 220642

E contact.4.gsk@gsk.com

www.gsk.com

August 7, 2018

Corporate Relations (Listing Department)
The Bombay Stock Exchange Ltd.
Stock Exchange Towers
Dalal Street, Fort
Mumbai - 400 023

Manager - Listing Department
National Stock Exchange of India Ltd.
C – 1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra (East)
Mumbai - 400 05

Dear Sir,

Sub: Unaudited Financial Results for quarter ended June 30, 2018

Pursuant to Regulation 33 and 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we would like to inform you that the Board of Directors in its meeting held on Tuesday, August 07, 2018 at 06:00 p.m. at Factory Conference Room, GlaxoSmithKline Consumer Healthcare Limited, Patiala Road, Nabha 147201 (Punjab) have, inter alia, considered and taken on record the Unaudited Financial Results for the quarter ended June 30, 2018.

We are enclosing a copy of the Unaudited Financial Results for the quarter ended June 30, 2018 along with the "Limited Review" Report, issued by the Auditors for the review done by them, for your records.

Thanking You

Yours faithfully For GlaxoSmithKline Consumer Healthcare Limited

Shanu Saksena Company Secretary M.No: FCS-9733

Encl: as above

Deloitte Haskins & Sells LLP

Chartered Accountants 7th Floor, Building 10, Tower B DLF Cyber City Complex DLF City Phase - II Gurugram - 122 002 Haryana, India

Tel: +91 124 679 2000 Fax: +91 124 679 2012

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF GlaxoSmithKline Consumer Healthcare Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of GlaxoSmithKline Consumer Healthcare Limited ("the Company"), for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP

Chartered Accountants (Firm's Registration No. 117366W/W-100018)

Manjula Banerj

Partner

(Membership No. 086423)

Nabha, August 7, 2018

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.





CIN: L24231PB1958PLC002257 Email ID: investor.2.co@gsk.com Website: www.gsk-ch.in

Statement of Unaudited Finan	icial Results for the Quarter en	ded June 30 2018		(Rs. in Lakhs)
Particulars	For the quarter ended			For the year ended
	30/06/2018	31/03/2018	30/06/2017	31/03/2018 Audited
	Unaudited	Audited (Refer Note 6)	Unaudited	
1 Income (a) Revenue from operations	11,07,14	11,79,58	10,46,41	43,77,05
(b) Other income	96,45	84,17	55,16	2,57,41
Total Income	12,03,59	12,63,75	11,01,57	46,34,46
2 Expenses			All districts and the second s	217.227
(a) Cost of materials consumed	3,09,08	3,15,90	3,16,76	12,51,96
(b) Purchase of stock-in-trade	24,88	32,53	29,89	1,39,64
(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	2,90	25,27	(4,04)	40,98
(d) Excise duty	224	2	60,54	60,54
(e) Employee benefits expense	1,67,97	1,37,59	1,31,20	5,27,73
(f) Depreciation and amortisation expense	14,70	14,54	17,01	64,37
(g) Other expenses		6		
(i) Advertising and promotion	1,43,89	1,69,26	1,27,84	5,46,73
(ii) Others	2,28,13	2,49,00	2,17,34	9,26,12
(h) Finance costs	18	77	2,17,34	2,03
Total Expenses	8,91,73	9,44,86	8,97,08	35,60,10
3 Profit before tax (1-2)	3,11,86	3,18,89	2,04,49	10,74,36
Income tax expense	5,22,03	5/25/25	77-17-1	
(a) Current tax	1,13,83	1,04,25	69,87	3,61,91
(b) Deferred tax	(2,41)	2,83	2,39	12,35
Total tax expense	1,11,42	1,07,08	72,26	3,74,26
5 Profit for the period (3-4)	2,00,44	2,11,81	1,32,23	7,00,10
6 Other comprehensive income				
(i) Items that will not be reclassified to profit or loss				
Remeasurements of post-employment benefit obligations	6,00	12,66	=	25,49
(ii) Income tax relating to items that will not be reclassified to profit or loss	(2,10)	(4,38)		(8,82)
Total other comprehensive income, net of income tax	3,90	8,28		16,67
7 Total comprehensive income for the period (5+6)	2,04,34	2,20,09	1,32,23	7,16,77
Paid up equity share capital	42,06	42,06	42,06	42,06
(Face value of Equity Shares)	10	10	10	10
9 Earnings per share (of Rs 10/- each) (not annualised): (a) Basic	47.66	50.36	31.44	166.47
(b) Diluted	47.66	50.36	31.44	166.47



Notes to the financial results:

- 1. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on August 7, 2018 and were subjected to a review by the statutory auditors. Results for the quarter ended June 30, 2017 were reviewed by previous auditors Price Waterhouse.
- 2. The above results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) -34, "Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3. Effective April 01, 2018, the Company has adopted Ind AS 115 'Revenue from Contracts with Customers'. The application of Ind AS 115 did not have any material impact on the financial results of the Company.
- 4. Consequent to introduction of Goods and Services Tax (GST) with effect from July 01, 2017, Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard, as applicable and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the quarter ended June 30, 2017 and for the year ended March 31, 2018 are not strictly relatable to current period numbers.
- 5. As the Company's business activity falls within a single operating segment namely "Nutrition", the disclosure requirements of Ind AS 108 "Operating segment" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, are not applicable.
- 6. The figures of the preceding quarter ended March 31, 2018 as reported in these financial results, are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2018 and the published year to date unaudited figures upto the third quarter of that financial year.
- 7. The figures for the previous periods have been reclassified/regrouped wherever required to confirm to the current periods presentation/classification. These are not material and do not affect the previously reported net profit or equity.

ON BEHALF OF THE BOARD OF DIRECTORS

Navneet Saluja Managing Director

DIN: 2183350

M

Place: Nabha

Date: August 07, 2018

d